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http://dx.doi.org/10.1We present a meta-analysis of somatic copy number alterations (CNAs) from 11 publications that
examined 662 prostate cancer patient samples, which were derived from 546 primary and 116
advanced tumors. Normalization, segmentation, and identification of corresponding CNAs for
meta-analysis was achieved using established commercial software. Unsupervised analysis
identified five genomic subgroups in which approximately 90% of the samples were characterized
by abnormal profiles with gains of 8q. The most common loss was 8p (NKX3.1). The CNA dis-
tribution in other genomic subgroups was characterized by losses at 2q, 3p, 5q, 6q, 13q, 16q,
17p, 18q, and PTEN (10q), and acquisition of 21q deletions associated with the TMPRSS2-
ERG fusion rearrangement. Parallel analysis of advanced and primary tumors in the cohort indi-
cated that genomic deletions of PTEN and the gene fusion were enriched in advanced disease. A
supervised analysis of the PTEN deletion and the fusion gene showed that PTEN deletion was
sufficient to impose higher levels of CNA. Moreover, the overall percentage of the genome
altered was significantly higher when PTEN was deleted, suggesting that this important genomic
subgroup was likely characterized by intrinsic chromosomal instability. Predicted alterations in
expression levels of candidate genes in each of the recurrent CNA regions characteristic of each
subgroup showed that signaling networks associated with cancer progression and genome sta-
bility were likely to be perturbed at the highest level in the PTEN deleted genomic subgroup.
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nancy in men and a leading cause of cancer deaths in
developed countries (1). Emerging prostate cancer genomic
data hold great promise not only in stratifying this hetero-
geneous disease at biopsy, but also in providing the
groundwork for future development of targeted therapies (2).
The frequencies of mutated genes in prostate cancer,
which are determined by sequence-based methods, are
surprisingly low, with TP53 (17%), TTN (15%), PTEN (11%),
MUC16 (9%), and SPOP (8%) (Catalogue of Somatic Mu-
tations in Cancer (COSMIC)) (3). In contrast, the frequency
of large-scale copy number alterations (CNAs) and genomic
rearrangements is significantly higher, suggesting that theary 16, 2014; received in revised form July 22,
ptember 7, 2014.
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016/j.cancergen.2014.09.003development and progression of prostate cancer is primarily
the result of an accumulation of larger-scale genomic aber-
rations, such as deletions, gains, and fusion gene formation
(4e6), instead of more localized mutational events.
Genomic rearrangements leading to the formation of
TMPRSS2-ETS gene fusions and deletion of the PTEN
tumor suppressor (10q23.31) often occur concurrently, and
are the most widely reported genomic biomarkers in prostate
cancer (7). The TMPRSS2-ERG gene fusion is the principle
ETS family prostate cancerespecific gene fusion, a char-
acteristic signature in approximately one half of prostatic
malignancies. PTEN deletions and the TMPRSS2-ERG
fusion genes are independently associated with aggressive
disease; likewise, concurrent exhibition portends a shorter
time to biochemical recurrence and decreased prostate
cancerespecific survival (8e12). Metastatic disease is por-
trayed by heightened genomic complexity as well as an
increased frequency of CNAs (7). Hormonal therapies forccess article under the CC BY-NC-ND license (http://creativecommons.
Prostate cancer genomic meta-analysis 475the treatment of advanced or recurrent disease often result
in genomic amplification of the androgen receptor locus (AR,
Xq11.2eq12), which is one of several mechanisms to
overcome androgen ablation regimens that results in the
development of castration-resistant prostate cancer (13).
In recent years, several prostate cancer cohort microarray
studies have been published, but interpretations have been
limited by the relatively small sample sizes, and rarely has
there been uniformity in the methods used for data analysis
between studies (5,6,14e26). Thus, the objective of this
study was to perform a systematic review and selection of
public domain prostate cancer genomic datasets, followed by
a comprehensive meta-analysis of the pooled data of 662
tumors to derive consensus data on the common CNAs. The
combined genomic data was then used to identify distinct
subgroups and associated candidate pathways of prostate
carcinogenesis that could be inferred from the diverse pat-
terns of genomic imbalance. The subgroups that were the
most distinct were tumors positive for PTEN deletions and/or
TMPRSS2-ERG fusion status. PTEN deletions were signifi-
cantly associated with a greater percent of the genome being
altered (PGA). Predicted changes in expression levels of
candidate genes that mapped to recurrent CNA regions
showed that signaling networks and canonical pathways
associated with cancer progression were more likely to be
perturbed in the PTEN deleted subgroups. The large size of
this meta-dataset permitted an in-depth survey and exami-
nation of concurrent losses and gains that consistently
associate within tumors, suggesting that previously unrec-
ognized relationships may exist between specific DNA
changes and recurrently targeted signaling pathways.
Methods
Collecting prostate cancer public genomic
datasets
High-resolution, human prostate cancer array comparative
genomic hybridization (aCGH) or single nucleotide poly-
morphism (SNP) microarray datasets were collected from
supplementary files of published manuscripts and the National
Center for Biotechnology Information’s (NCBI) Gene Expres-
sion Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) using
“prostate cancer” with “aCGH”, “copy number”, or “SNP” as
keyword combinations. Querying the ArrayExpress (http://
www.ebi.ac.uk) database did not reveal any additional data-
sets. Six Agilent (Santa Clara, CA) aCGH datasets
(6,18,19,22e24) and five Affymetrix (Santa Clara, CA) data-
sets (14,15,17,20,21) were integrated to create a prostate
cancer genomic copy number meta-dataset (Table 1).
A total of 879 raw genomic microarray files were
collected, including primary and advanced prostate cancers,
HGPIN lesions, cell lines, and xenografts, as well as
matched normal tissues (Table S1). The overall workflow for
this meta-analysis is shown in Figure 1.
A total of 11 datasets were incorporated to build the meta-
dataset, which is referenced by GEO accession numbers
and PubMed IDs in Table 1. The platform used in each case
is mentioned as well as a breakdown of the sample type. The
right side of the table displays the number and type of
samples that passed quality control inspection, the numberand type of unique samples that were included, as well as the
number of samples excluded from the analysis and the
reason why. High-grade prostatic intraepithelial neoplasia
(HGPIN), cell lines, and xenograft samples were not included
in the analysis due to the same sample size and matched
benign controls being used as baseline when available for
Affymetrix data.
Reported clinical characteristics of patient tumors
in the pooled study group
The final pool comprised 568 primary prostate cancer
tumor samples from a total of 545 men who were diagnosed
with clinically localized prostate cancer after radical pro-
statectomy. The primary unique tumors analyzed in this
study were derived from eight published manuscripts
(6,14,15,17e20,24). Further details specific to the different
samples, including the patient with more than one unique
tumor, can be found in the Supplemental Methods. In most
cases, the tumors were staged using the 2002 TNM classi-
fication of malignant tumors (27) and graded according to the
revised Gleason Grading system (28). The distribution of the
Gleason Grade (available for 350 (61.6%) primary tumors)
was as follows: 149 of 350 (42.6%) had Gleason Grade 5 or
6, 156 of 350 (44.6%) had Gleason Grade 7, and 37 of 350
(10.6%) had Gleason Grade 8 or higher. The 161 advanced
prostate cancers (158 (98.1%) were distant metastatic le-
sions) included in this study were derived from 115 men
obtained from five published manuscripts (6,19,21e23). Of
these advanced cases, 89 (77.4%) were castration-resistant
metastatic prostate cancer. Further details, as available, of
the clinical characteristics of the 729 tumors included in this
study are provided in Table S1.
Sample quality control, inclusion, and exclusion
criteria
The raw copy number data files from 568 primary, 161
advanced, 13 HGPIN, and 120 benign control samples, as
well as 17 cell line or xenograft samples, were downloaded,
which amounted to 879 raw data copy number profiles
(Figure 1, Tables 1 and S1). Sample exclusion criteria
included: (1) corrupt raw data files (2 samples); (2) raw data
of poor quality (5 samples); and, for benign samples, (3)
profiles that exhibited large or prostate cancerelike CNAs
believed to be potentially contaminated with adjacent tumor
tissue (10 samples). A total of 563 primary, 161 advanced,
12 HGPIN, and 110 matched benign samples remained after
quality control verification. Cell lines and xenografts were
excluded from the analysis. To ensure the integrity of the
meta-dataset, only unique samples were included in the
analysis. Unique samples were defined as a single sample
per patient tumor type. In cases where multiple primary,
HGPIN, or metastatic foci were collected for a particular
patient, incorporation of the sample harboring the greatest
number of aberrations was selected (14,15,21,22). There-
fore, final exclusion criteria also included one tumor focus/
patient tumor type (62 samples). In only two cases (one
primary and one advanced) were two samples kept for an
individual patient tumor type, because each sample exhibited
an aberrant yet different copy number profile (Figure S1)
Table 1 Prostate cancer genomic meta-dataset
GSE no. Platform Neoplastic samples downloaded
Additional samples 
dowloaded
Total samples        
(passed QC analysis) Excluded Total unique samples Reference PMID
GSE20393 Agilent 244K 58 primary 0 58 primary 0 58 primary (18) 20668451
GSE21032 Agilent 244K 181 primary/37 advanced 13 cell lines/xenografts 180 primary/37 advanced 1
b 180 primary/37advanced 20579941
GSE34174 Agilent 244K 15 advanced 0 15 advanced 1d 14 advanced 22158653
GSE35988 Agilent 105K (119 primary); Agilent 244K (3 advanced) 59 primary/35 advanced 28 benign
59 primary/35 
advanced 1
c 59 primary/35 advanced 22722839
GSE28403 Agilent 44K 2 primary/16 advanced 0 2 primary/16 advanced 0
2 primary + 16 advanced 
(15 patients) 21919029
GSE29229 Agilent 44K 86 primary 0 84 primary 1a + 1b 84 primary 22179824
GSE14996 Affymetrix SNP 6.0 58 advanced 16 benign 58 advanced 1c + 44d 14 advanced 19363497
GSE29569 Affymetrix SNP 6.0 35 primary/13 HGPIN 18 benign 33 primary/12 HGPIN 1
a + 2b + 2c + 16d 19 primary (18 patients) 22334418
GSE18333 Affymetrix SNP 6.0 44 primary 38 benign 44 primary 6c + 3d 41 primary 20516122
GSE12072 Affymetrix 500K SNP 20 primary 20 benign 20 primary 0 20 primary 19242612
GSE19399 Affymetrix 250K SNP 83 primary 4 cell lines 83 primary 0 83 primary 20164920
n = 736   
563 primary          
161 advanced         
12 HGPIN
n = 80   
6 incompatable       
64 duplicates        
10 controls
n = 672
546 primary              
116 advanced             
10 HGPIN
Total acceptable files (n = 863)
563 primary / 161 advanced / 12 HGPIN /
27 Agilent control / 83 Aﬀymetrix control /
17 cell lines or xenogras
Total downloaded files (n = 879)
568 primary / 161 advanced / 13 HGPIN/
28 Agilent control / 92 Aﬀymetrix control / 17 cell lines or xenogras
Downloaded ﬁles Incorporated neoplasc samples
(6)
(22)
(19)
(23)
(24)
(21)
(15)
(14)
(20)
(17)
Abbreviation: PMID, PubMed Identifier.
aFiles were corrupt and unable to be processed by Nexus Copy Number microarray analytical software.
bFiles removed due to poor quality control, resulting in undetectable CNAs.
cBenign controls removed as a result of harboring prostate-specific CNAs.
dPatient duplicates removed for frequency analysis.
476 J.L. Williams et al.(15,23). A total of 546 primary, 116 advanced, and 10 HGPIN
unique samples remained in the pooled study group. The
HGPIN samples will not be discussed further due to the small
cohort size.Raw data analysis and CNA assignment
Nexus Copy Number, v7.0 (BioDiscovery) is a platform-
independent microarray analytical software for the incorpo-
ration and co-analysis of genomic microarray datasets from
various sources (Figure S2). The algorithms contained within
the copy number application of the software perform the
normalization, segmentation, and identification of corre-
sponding copy number events from the raw data of all
genomic files within a single project, using build 37 (human
genome 19) of the genome as the common scaffold for all
tumor profiles. Details concerning methods of data integra-
tion and probe spatial relationships of the various Agilent and
Affymetrix datasets are provided in the Supplemental
Methods. Specific settings and algorithm details can also
be found in the Supplemental Methods, as well as Tables S1
and S2. To accurately define hemizygous or homozygous
deletions and, similarly, gain or amplification -(high-level
gain), each individual genomic profile was examined,
ensuring the probes were centered at a log ratio of 0 or no
copy change, while noting the extent of gain or loss in any
given region of the genome and utilizing known regions of
homozygous (8p, 13q, PTEN ) and hemizygous (PTEN, the
TMPRSS2-ERG (Edel) gene fusion) deletions to accuratelychoose appropriate limitations of hemizygous and homozy-
gous thresholds (Supplemental Methods).
Detection of fusion rearrangements by genomic
microarrays
Analysis of microarray copy number profiles, specifically
deletions of 21q22.2eq22.3 (39.9e42.8 Mb), infers the
presence of the classic TMPRSS2-ERG gene fusion rear-
rangement known as “Edel” (6,12) (Figure S3). “Esplit”
TMPRSS2-ERG gene fusions retain the intervening se-
quences within the nuclei, in a copy neutral manner;
consequently, microarray copy number data cannot always
identify this fusion rearrangement. Nevertheless, small de-
letion(s) at either ERG (39.7-39.9 Mb), TMPRSS2 (42.8 Mb),
or both breakpoints were considered indicative of an alter-
native 50 (androgen regulated or ubiquitously expressed
promoter), or 30 (ETS transcription factor) partner, or Esplit
fusions, respectively (6).
Unsupervised hierarchical clustering
Complete linkage hierarchical clustering (CLHc) was per-
formed on the 546 unique primary prostate tumors, which
divided the cohort into three groups of genomic alterations.
The K-means clustering algorithm (k Z 3) was used to
determine if any subgroupings existed within the 8p-deleted
tumors. The five unsupervised primary clusters (A, B, C1,
C2, C3) represent the first set of genomic subgroups of this
Figure 1 Workflow for prostate cancer meta-dataset and combined analysis. The gray and three light red panels depict the steps for
sample selection and initial CNA profiling. The pale blue panels demonstrate the analytical steps used to investigate the genomic
groupings and association of CNAs with signaling pathways. Superimposed squares indicate the collection, inclusion, and distribution
of samples throughout the various steps and analyses. NCBI’s Gene Expression Omnibus (GEO) was searched using the keywords
“prostate cancer” with “aCGH”, “copy number”, or “SNP”. A total of 11 high-resolution human prostate cancer genomic datasets were
collected, which contained 879 individual samples related to prostate cancer patients (Table 1). The 879 genomic samples were
queried using BioDiscovery’s (Santa Clara, CA) Nexus Copy Number microarray software, and the FASST2 segmentation algorithm
was applied to determine CN profiles for each sample. Following quality assessment, 546 unique primary and 116 unique advanced
samples were incorporated. Copy number events were ascertained for each sample, which permitted an examination of differences
within and between the primary and advanced populations. Stratification of the primary cohort (blue panels) was performed using
several different mechanisms to determine the most informative genomic groupings of prostate cancer. Unsupervised clustering of the
primary prostate cancers produced five genomic subgroups: A, B, C1, C2, and C3. Supervised classification based on PTEN deletions
or the gene fusion was also performed, which created PTEN intact/loss and FUSION ve/þve genomic subdivisions. PTEN and fusion
gene levels were compared between primary and advanced samples. Assessment of genomic instability and exploration of perturbed
signaling pathways was performed to explore biological and potential clinically significant differences between the various genomic
subdivisions.
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on frequency of copy number alteration without taking bio-
logical relevance into consideration, which is why supervised
classifications based on rearrangements with clinical signifi-
cance were subsequently pursued.Supervised subgroup classification based on
PTEN deletions and fusion status
The supervised analysis comprised three main comparisons
of the cohorts: (1) an overall analysis of the entire cohort of
662 samples (including both primary and advanced tumors);
(2) an analysis of the 546 primary tumor samples; and (3) ananalysis of the 116 advanced tumor samples. For each
comparison, samples were subdivided based on PTEN
(10q23.31, 89.6e89.7 Mb) deletion and TMPRSS2-ERG
gene fusion (21q22.2eq22.3) status. Each cohort was spe-
cifically analyzed for differences in samples that contained
each rearrangement alone (PTEN deletion vs. PTEN intact;
fusion-positive vs. fusion-negative) or in combination (fusion-
negative/PTEN intact; fusion-positive/PTEN intact; fusion-
negative/PTEN deleted; and fusion-positive/PTEN deleted).
Ultimately, the cohort was divided based on PTEN or
fusion gene status, and the genomic profiles were directly
compared. Association of different genomic regions with the
presence or absence of PTEN deletions or fusion events was
based on P-values obtained from the Student t-test, and the
478 J.L. Williams et al.CNA associations were graphically depicted using circos
plots from the concordance function in Nexus Copy Number,
v7.0 (BioDiscovery).Genomic instability assessment
The frequency of samples harboring losses and gains at
specific genomic intervals commonly gained or lost in pri-
mary prostate cancer were enumerated and compared be-
tween genomic groups (see Table S3). The genomic
instability metric, the percentage of genome altered (PGA), is
the percentage of base pairs lost or gained relative to the
entire genome (NCBI hg19 database (GRCh37.p13)
comprising 3,095,677,412 base pairs; http://www.ncbi.nlm.
nih.gov/projects/genome/assembly/grc/human/data/index.
shtml). Examining genomic instability by these two appro-
aches (frequency of CNAs across the genome and PGA)
provided a much more comprehensive appreciation of the
integrity of the genome.Pathways implicated in different genomic
subgroups based on imputed expression levels
Since only one of the eight CNA datasets had accompanying
gene expression data, it was necessary to impute relative
levels of gene expression weighted by whether a particular
region of interest was subject to loss (i.e., reduced expres-
sion levels assigned) or to gain (i.e., increased expression
assigned). To select genes within a given genomic interval,
arbitrary cut-offs above background were chosen to identify
the genes specific to each subgroup and to identify signaling
pathways that may be perturbed by the CNAs that are
characteristic of a particular subgroup. Gene lists were
compiled for each genomic subgroup: genes recurrently
deleted (in 25% and 5% of the samples for hemizygous and
homozygous deletions, respectively) or gained (in 10% of
the samples). In this way, simulated expression levels were
created based on the genes that were present in a given
subgroup, taking into account the direction of copy number
change and proportion of samples within that subgroup with
the specific alteration (Table S4). Genes in regions of poly-
morphic copy number variation or in close proximity to telo-
meres or centromeres were excluded. Benign profiles were
consulted and demonstrated similar peaks in these same
regions (Figure S4). The “Core Analysis” function in Ingenuity
Pathway Analysis (Ingenuity Systems, http://www.ingenuity.
com) was used to explore each of the eight genomic sub-
groups in the context of biological functions and canonical
pathways. For the general settings, the “Ingenuity Knowl-
edge Base (Genes Only)” reference set was used as the
population of genes to consider for P-value calculations, and
both direct and indirect relationships were included. For the
analysis filter summary, we considered only molecules and/
or relationships where species equaled human or mouse or
rat. The significance of the biological functions and canonical
pathways implicated as perturbed in a subgroup’s gene list
was determined by the Fisher exact test P-value. For each
analysis, a maximum of 25 molecular interaction networks
containing a maximum of 35 nodes each were generated.Statistical analysis
The association between particular CNAs was assessed
using the chi-square test, and differences in the frequencies
of CNAs between subgroupings were computed using the
Student t-test. The comparisons between the various sub-
groups were performed using the Fisher exact test. All sta-
tistical analyses were performed using IBM SPSS Statistics,
v21 (IBM Corporation, Armonk, NY).Results
The frequencies of recurrent CNAs were calculated across
the entire genome and grouped into deletions and gains
(Table 2, Figures 2 and S5) for all 662 prostate cancer
samples (546 primary tumors and 116 advanced cohort)
derived from the 11 genomic copy number datasets. A total
of 14 regions of recurrent deletion and 5 regions of recurrent
gain were identified in the combined dataset (Table 2). The
cytobands spanning the region, the entire region (Location),
the minimal region of overlap (MRO), and genes of particular
interest to prostate cancer are listed for each CNA.
Systematic PubMed literature and cancer Gene Census
(29) searches supplemented by recent COSMIC (3,30)
findings were used to establish candidate driver genes for
each region of imbalance shown under the profiles in
Figure 2. Mining of Progenetix prostate cancer data (592
chromosomal CGH and 95 aCGH samples) confirmed the
genes and regions of imbalance identified in this meta-
analysis (31,32).Recurrent deletions
As previously reported (4), deletion of chromosome 8p
(8p23.3ep11.21; 1e43 Mb) was the most recurrent CNA
observed in the prostate cancer genome, with 409 of 662
(61.8%) prostate tumors being affected. Losses of 8p were
found in 304 of 546 (55.7%) and 105 of 116 (90.5%) cases of
localized and advanced prostate carcinoma, respectively.
The minimal region of deletion occurs in the interval
8p21.3ep21.2, which contains the prostate-specific tumor
suppressor, NKX3-1, at cytoband 8p21.2. Deletions in 8p
display a unimodal distribution of loss extending in both di-
rections along the 8p arm. Telomerically, the deletion fre-
quency diminishes to approximately 40% mid-8p22.2 before
decreasing to approximately 35% of samples exhibiting
deletion of the 8p telomeric region. Centromerically, the
deletion frequency decreases to approximately 25%
(approximately 20% in primary and approximately 35% in
advanced) at 8p11.21. The deletion profile showed a sharp
decline at the 8p pericentromeric region in the primary tu-
mors and returned to a copy neutral or gained state on 8q;
however, in approximately 19% of advanced tumors, the
deletion interval was much larger, extending into the q arm at
8q11.21 and diminishing below background by 8q13.1
(66 Mb).
The second most frequent deletion detected in prostate
cancer is the extensive genomic region surrounding the RB1
tumor suppressor gene, comprising the following cytobands,
13q13.1eq31.1 (33e86 Mb), with the deletion frequently
Table 2 Recurrent genomic imbalances identified in prostate cancer
n % n % n % Region Cytobands Loca on (Mb) MRO (Mb) Genes
193 29.2 137 25.1 56 48.3 Fusion 21q22.2–q22.3 40.0 –42.8 ERG, TMPRSS2
205 31.0 124 22.7 81 69.8 PTEN 10q23.31 Gene only PTEN
196 29.6 125 22.9 71 61.2 Del_2q 2q14.1–q24.2 117–160 CXCR4
145 21.9 108 19.8 37 31.9 Del_3p13 3p13 71–74 FOXP1, RYBP, SHQ1
284 42.9 196 35.9 88 75.9 Del_5q 5q11.2–q23.3 54.8–128 CHD1, APC
309 46.7 223 40.8 86 74.1 Del_6q 6q12–q22.33 MAP3K7
409 61.8 304 55.7 105 90.5 Del_8p 8p23.3–p11.21b NKX3-1
240 36.3 144 26.4 96 82.8 Del_10q PTEN
191 28.9 130 23.8 61 52.6 Del_12p CDKN1B
350 52.9 245 44.9 105 90.5 Del_13q BRCA2, RB1
346 52.3 242 44.3 104 89.7 Del_16q CDH1
245 37.0 155 28.4 90 77.6 Del_17p 7.5 TP53
143 21.6 95 17.4 48 41.4 Del_17q BRCA1, ETV4
217 32.8 139 25.5 78 67.2 Del_18q SMAD4, BCL2
124 18.7 53 9.7 71 61.2 Gain_3q PIK3CA, ETV5
164 24.8 77 14.1 87 75.0 Gain_7 whole chromosome gain ETV1, EGFR, MCM7, BRAF
211 31.9 114 20.9 97 83.6 Gain_8q 128.8 MYC
174 26.3 100 18.3 74 63.8 Gain_16p whole arm gain -
83 12.5 23 4.2 60 51.7 Gain_20q 55-62.9 -
Prostate cancer
(N= 662)
Primary
(N= 546)
Advanced
(N= 116)
Region informa on
10q23.2–q26.12
12p13.31–p12.3
13q12.3–q31.1†
16q11.2–q24.3
17p13.3–17p11.2
17q21.2–q21.31
18q12.1–q23
3q13.33–q27.3
7p22.3–q36.2
8q11.21–q24.3
16p13.3–p11.2
20q11.22–q13.33
63.9–129.7
2.9–42.1
88–131.4
7.8–17.9
32.1–110.3
46.6–88.8
2.2–18.3
40.5–42.3
26.1–76.7
120.9–187.8
1.5–153
48.8–142.9
1.1–33.6
32.2–62.9
89.6–89.7
136.2–137.2
71.9–72.9
66.8–73.2 & 98–103
88.1–93.1
21.9–25.1
89.6–89.7
11.8–13.8
48.1–50.1
85.2–90.2
41.1–41.7
71.2–76.7
140–170
39.9 & 42.8
Abbreviation: MRO, minimal region of overlap.
aPrimary and Advanced combined.
bAberration extends in advanced cases.
Prostate cancer genomic meta-analysis 479encompassing the 13q telomeric region in advanced tumors.
A total of 350 of 662 (52.9%) prostate cancers, (245 of 546
(44.9%) primaries, and 105 of 116 (90.5%) advanced cases)
harbored a deletion within this genomic interval, with theFigure 2 Recurrent genomic copy number alterations in prostate c
software (BioDiscovery). The genome is displayed horizontally, and t
axis. Red and dark red represent regions of hemizygous and homo
gions of gain and amplification, respectively. Systematic COSMIC, P
candidate driver genes for each region of imbalance. *Genes that h
fusion partners.minimal region of deletion occurring at cytoband 13q14.2,
which contains the RB1 gene locus. The configuration of the
13q deletion has a bimodal trend, with a weak secondary
peak at 13q21.33 (73 Mb) in the primary cohort.ancer. Snapshot from Nexus Copy Number microarray analytical
he frequency of CNA at any given location is displayed on the y-
zygous deletions, respectively; blue and dark blue represent re-
ubMed literature, and cancer Gene Census searches identified
ave been identified as alternative 30 or 50 prostate cancer gene
480 J.L. Williams et al.Deletions at 16q22.1eq24.3 (entire 16q arm in
advanced disease) and 6q12eq22.33 followed as the third
and fourth most common deletions observed in prostate
cancer. The remaining recurrent deletions, in order of
prevalence in primary disease were: 5q11.2eq23.3,
17p13.3ep11.2, 10q23.2eq26.12, 18q, 21q22.2eq22.3
(gene fusion), 12p13.31ep12.1, 2q14.1eq24.1, 3p13, and
17q21.2e21.31.
Recurrent gains
Chromosome 8q was the most frequent gain observed in
this meta-analysis dataset, with 211 of 662 (31.9%) tumors
harboring extra copies of 8q. Chromosome 8q gain was
identified in 114 of 546 (20.9%) and 97 of 116 (83.6%)
primary and advanced cases, respectively. The pattern of
gain along the long arm of chromosome 8q has an
extensive region of consistent gain across the entire arm
(8q11.21eq24.3) in both primary and advanced disease.
Within this region of 8q gain, advanced disease cases
often have a small focal region of high gain at the
cytoband 8q24.21, which corresponds to the MYC onco-
gene (Table 2). Additional gains observed in primary dis-
ease are quite infrequent but include gain of 16p (100 of
546, 18.3%), the entire chromosome 7 (77 of 546, 14.1%),
3q (53 of 546, 9.7%), and 20p (23 of 546, 4.2%).
Gain of chromosome 7 was also frequent, with 164 of 662
(24.8%) prostate tumors harboring gains encompassing the
entire chromosome when primary and advanced tumors
were combined. Gains in the 16p arm (100 of 546, 18.3%,
and 74 of 116, 63.8%, in primary and advanced tumors,
respectively) were identified at a higher frequency than
chromosome 7 gains in the primary cohort.
Gleason Scores and CNAs
Genomic copy number profiles of the primary cohort stratified
by Gleason Score were created for the 309 primary tumor
samples from which data were available for comparison. The
133 cases of Gleason 6 were indistinguishable from the 141
Gleason 7 cases when overall profiles were examined. There
was a more marked distribution of CNAs, which suggested a
greater frequency of alterations in the 33 tumors with Glea-
son 8 (Figure S6).
Genomic rearrangements specific to advanced
disease
Gain of chromosome 7 was the second most common gain
and was identified in 74 of 116 (63.8%) advanced disease
cases; this is in stark contrast to the low frequency and
third ranked position of chromosome 7 gains in primary
disease. Subsequently, the AR gene locus on chromosome
X (Xq12; 76 of 116, 65.5%) ranks third in advanced dis-
ease gains. The extra copies of the AR gene found in the
advanced disease cohort relative to the 2.9% observed in
the primary tumor cohort was consistent with mechanisms
to overcome the androgen blockade imposed by anti-
androgens and chemical castration treatments to combat
advanced recurrent prostate carcinoma. Chromosomes16p (63.8%), 3q (61.2%), and 20q (51.7%) were
also identified as frequent regions of gain in advanced
disease.Unsupervised clustering identified three major
genomic subgroups
Unsupervised hierarchical clustering was used to generate a
dendrogram of the 546 unique primary prostate cancer
samples (Figure 3). The cluster analysis produced three
main genomic branches. Further segregation beyond three
clusters using the CLHc algorithm produced an increasing
number of small clusters, while always maintaining a large
proportion of samples in a single cluster. This was not
informative, for example, when the CLHc was used to define
the six clusters into which the cohort was divided: 52 (9.5%),
55 (10.1%), 356 (65.2%), 38 (6.9%), 6, (1.1%), and 39
(7.1%) (Figure S7). The most informative CLHc produced
three subdivisions: a group that was genomically benign and
lacked any consistent CNAs (“A”); a group that lacked the
most common CNA, 8p deletions (“B”); and the 8p-deleted
tumors that contained a wide range of additional CNAs (“C”).
Subgroup A lacked any consistent genomic imbalances (nZ
55, 10.1% of the samples). Subgroups B and C each had 6q
losses accompanied by gains of chromosomes 7 and 8q.
The subgroup B (n Z 52, 9.5% of samples) branch of the
dendrogram was classified by the absence of 8p deletions.
The other CNAs within the branch included losses at 2q, 5q,
13q, and 16q. The most prevalent subgroup, C (n Z 439,
80.6% of samples), was characterized by the presence of 8p
deletions together with several other large-scale CNA
alterations.
The 8p-deleted samples (“C”, n Z 439) were partitioned
into three related genomic subgroup branches (C1-3),
based on their individual CNA profiles. K-means clustering
permitted segregation of the large cohort of 8p-deleted tu-
mors (K-means was uninformative when used on the entire
primary cohort; see Figure S8). Subgroup C1 was charac-
terized by 2q, 6q, 8p, and 13q deletions; however, chro-
mosomal losses at 5q, 16q, 17p, and 18q, as well as PTEN
and fusion rearrangements, were not apparent in this sub-
group (n Z 55, 10.1%). In contrast, subgroups C2 and C3
harbored the majority of the PTEN deletions and fusion
genes, with several additional chromosomal losses
commonly identified in prostate cancer. One apparent
distinction of C2 tumors is the absence of 13q deletions (n
Z 52, 9.5%), whereas C3 tumors (n Z 332, 60.8%) had a
greater frequency of CNAs across the entire genome,
including the common 13q deletion. Although the overall
levels of differential genomic CNA observed within each of
the subgroup C arms was minor, the pattern of alterations
suggested that acquisition of PTEN genomic deletions and/
or the TMPRSS2-ERG fusion may underlie the distinction
between C1 and C2/C3 tumors. We therefore undertook a
more detailed evaluation of genomic subgroupings based
on the presence or absence of the PTEN deletion and
TMPRSS2-ERG fusions in the cohort.
Unsupervised clustering (CLHc and K-means) of the
advanced cohort was unsuccessful because samples were
disproportionately allocated into the derivative clusters (data
not shown).
Figure 3 Unsupervised clustering of primary prostate cancer. (A) Complete linkage hierarchical clustering. The dendrogram depicts
the hierarchical separation of the 546 primary samples into three clusters and the corresponding CNA profiles: (A) genomically benign
(nZ 55); (B) absence of 8p deletions (nZ 52); and (C) presence of 8p deletions (nZ 439). The genome is displayed horizontally and
the frequency of CNA in each cluster at any given location is displayed on the y-axis. (B) K-means, k Z 3. An unsupervised non-
hierarchical clustering was then performed to further subdivide the 439 8p-deleted primary prostate cancer tumors. The 8p-deleted
tumors were further subdivided into three subgroups: C1, an absence of PTEN and fusion rearrangements (nZ 55); C2, an absence
of 13q deletions (n Z 52); and C3, the presence of PTEN and/or fusion gene deletions (n Z 332).
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PTEN deletions and ETS gene fusions are frequently con-
current events in prostate cancer; thus, CNAs affecting these
regions were examined in more detail (8,33). PTEN deletions
were identified in 205 of 662 (31.0%) prostate cancer cases
(124 of 546 (22.7%) primary and 81 of 116 (69.8%)
advanced cases). The PTEN deletions were then charac-
terized as either hemizygous or homozygous deletions
(Table 3), where 96 and 28 of 546 (17.6% and 5.1%) primary
cancers harbored a detectable hemizygous or homozygous
deletion, respectively (Figures S9 and S10). PTEN deletion
frequency and fusion status for the meta-dataset are pre-
sented in Table 3. PTEN loss is stratified by the extent of
deletion, and positive fusion status is arranged according to
the mechanism of rearrangement: Edel or another mecha-
nism. The frequencies of the PTEN and fusion supervised
classifications are displayed in the table. A significantly
greater proportion of advanced samples harbored both
rearrangements when compared with the primary cohort.
Conversely, advanced disease samples not only harbored
an elevated frequency of PTEN genomic losses (69.8% vs.
22.7%), but also a significantly greater proportion (Fisher
exact test, P > 0.0001) of homozygous deletions: 18 (15.5%)and 63 (54.3%) of 116 advanced tumors harbored a detect-
able hemizygous or homozygous deletion, respectively. The
deletion pattern observed on chromosome 10 in primary dis-
ease corresponds very specifically to an interstitial focal
deletion centered on the PTEN genomic locus. In cases
where additional regions are involved, the deletion more
frequently extends in a telomeric direction, which is consistent
with the PTEN deletion fluorescence in situ hybridization
(FISH) findings from our laboratory (34). The rearrangements
on chromosome 10 also exhibit a more complex pattern of
chromosome 10 imbalance in the advanced cohort compared
to the overall trend of focal interstitial deletions targeting the
PTEN genomic locus in primary disease. Furthermore, when
comparing PTEN deleted samples to those without PTEN
deletions in the primary cohort, tumors with an intact PTEN
locus had almost no detectable CNAs targeting chromosome
10 (Figure 4viii and 4ix).
The most prevalent TMPRSS2-ERG fusion rearrange-
ment, “Edel”, results from deletion of 21q22.2eq22.3 fusing
the 50 untranslated region of TMPRSS2 (21q22.3) to the
coding sequence of ERG (21q22.2). This typical CNA was
identified in 145 of 662 (21.9%) prostate cancers, with 104
of 546 (19.0%) and 41 of 116 (35.3%) samples from primary
and advanced disease, respectively (Figures S3 and S11)
Table 3 Frequency of PTEN and fusion rearrangements in prostate cancer
PTEN hemizygous
PTEN homozygous
PTEN 187.220.13502ssol
TMPRSS2-ERG Edel
Fusion other
Fusion 651.522.92391)latot(
loss 114 17.2 17.6 18
loss 91 13.7 5.1 63
145 21.9 19.0 41
48 7.3 6.0 15
362 54.7 61.2 28
95 14.4 16.1 7
107 16.2 13.7 32
98 14.8
421
731
96
28
104
33
334
88
75
49 9.0 49
Advanced
PTENintact/fusionn-egaƟve
PTENintact/fusion-posiƟve
PTENloss/fusion-negaƟve
PTENloss/fusion-posiƟve
(N=116)
15.5
54.3
69.8
35.3
12.9
48.3
24.1
6.0
27.6
42.2
n  %
Primary
(N=546)
n  %
Prostate cancera
(N=662)
n  %
aPrimary and Advanced combined.
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were found to harbor a deletion at either the ERG break-
point (suggestive of an alternate 50 partner), the TMPRSS2
breakpoint (indicating an alternate 30 ETS partner), or at
both breakpoints (representative of the “Esplit” TMPRSS2-
ERG gene fusion rearrangement where the intervening
sequences are retained but relocated elsewhere in the
genome) (6,12). A significant association occurred between
the PTEN deletions and gene fusions by the chi-square
statistic (P < 0.001) in both primary and advanced co-
horts. A significant shift (P > 0.0001) also occurred in the
distribution when comparing primary and advanced cohorts
with the smallest fraction of primary tumors (9%), but the
majority (42%) of the advanced tumors harbored both
rearrangements (Table 3). The advanced cohort was
significantly enriched for both PTEN deletions and/or the
gene fusion (75.9% compared with 38.8% of primary sam-
ples). These data suggested that a supervised analysis of
the genomic influence of a PTEN deletion and gene fusion
rearrangements on the primary cohort may be highly
informative.Supervised classification with respect to PTEN
deletions and fusion genes
To determine how the presence or absence of a PTEN
deletion and fusion rearrangement affected the overall CNA
distribution within the primary cohort, we undertook a series
of comparisons of their combined effect on profiles in
Figure 4ie4iv, followed by an evaluation of their individual
effects in Figure 4ve4x.
The genomic profiles were initially subjected to a four-way
supervised classification in which the 546 primary tumors
were used to generate CNA profiles from the subset bearing
neither a PTEN deletion nor fusion rearrangements (see
Figure 4i). Similarly, the subset derived from samples with
just the gene fusion is shown in Figure 4ii, those with just a
PTEN deletion in Figure 4iii, and those samples bearing both
a PTEN deletion and a fusion rearrangement in Figure 4iv.
By comparing the two profiles in Figure 4i and 4ii to the two
profiles in Figure 4iii and 4iv, it is possible to directly infer the
overall influence of a PTEN deletion in comparison to thefusion rearrangement. It can be seen that strong similarities
exist between profiles in Figure 4i and 4ii (both with intact
PTEN ), with only minor CNAs evident along the genome.
Likewise, the profiles in Figure 4iii and 4iv, both with PTEN
deletions, are very similar. The presence of a PTEN deletion
seems to be strongly associated with more extreme copy
number differences and a wider distribution of CNAs along
the genome. Collectively, the profiles in Figure 4ie4iv sug-
gest that the presence of a PTEN deletion may have a more
general influence on the extent of CNAs in other regions of
the genome. In contrast, the fusion rearrangement has less
overall influence on the distribution or level of CNAs along
the genome.
Figure 4ve4vii provides profiles of the CNA intensity and
distribution along the genome in which a pairwise compari-
son of the consensus from samples without a fusion
(Figure 4v) is made against samples with a fusion rear-
rangement (Figure 4vi). In Figure 4vii, the fusion-negative
imbalance profile was used as a baseline reference against
the fusion-positive profile to obtain the enriched CNA distri-
bution that is strongly associated with the presence of a
fusion rearrangement. It can be seen that losses at 3p13, 8p,
10q, 16q, and 17p accompany the 21q deletion that was
used to define fusion events.
Figure 4viiie4x provides a similar pairwise comparison of
CNA intensity and distribution along the genome; differenti-
ating the CNA distribution of the PTEN gene intact samples
(Figure 4viii) relative to PTEN deleted samples (Figure 4ix).
In Figure 4x, the PTEN intact imbalances are used as a
baseline reference against PTEN deleted samples to provide
a more specific evaluation of the CNAs associated with
PTEN deleted samples. It can be seen that the influence of a
PTEN deletion leads to more extreme copy number differ-
ences and a wider distribution of CNAs along the genome
(Figure 4x). Moreover, regions of losses associated with the
PTEN deletion at 10q included losses at 3p13, 8p, 13q, 16q,
17p, and 21q. Gain at 8q was also present. Overall, a
significantly greater proportion of differential CNAs was
found when stratifying the primary cohort by PTEN
(Figure 4x) than when the gene fusion was used (Figure 4vii).
In summary, this analysis showed that the overall pattern of
CNAs is influenced predominantly by PTEN deletions instead
of the fusion gene status per se. Ultimately, two distinct
Figure 4 Influence of PTEN deletion and fusion rearrangement on CNAs. The genome is displayed horizontally, and the frequency
of CNA at any given location is displayed on the y-axis. Panels ieiv show a four-way classification of CNAs, which is stratified
according to status of fusion gene rearrangements and PTEN deletion status as indicated in each panel. It can be seen that strong
similarities exist between panels i and ii (both PTEN intact), with only a small number of CNAs evident along the genome. Panels iii
and iv (both PTEN deleted) also have very similar overall profiles, but a much more extensive and extreme distribution of CNAs is
present. In contrast, the presence (panels ii and iv) or absence (panels i and iii) of the fusion rearrangement did not seem to influence
the overall CNA profile. Panel v shows all samples with a fusion, and panel vi shows all samples without a fusion rearrangement. In
panel vii, the fusion-negative imbalance profile was used as a baseline reference against the fusion-positive profile to obtain the
consensus CNA distribution that is associated with the presence of the fusion rearrangement. In panel viii, PTEN gene intact samples
can be compared to PTEN deleted samples (panel ix). In panel x, PTEN intact imbalances are used as a baseline reference against
PTEN deleted samples to show the consensus CNAs associated with PTEN deleted samples. It can be seen that the influence
of PTEN deletion leads to more extreme copy number differences and a wider distribution of CNAs along the genome (panel x).
(Figure Continues)
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Figure 4 (Continued) Panels xiexii provide circos plots of a statistical comparison of the regions of CNAs associated with PTEN
deletion (panel xi) and fusion rearrangement (panel xii). In these analyses, the candidate driver genes from Figure 2 have been
assigned to the regions of recurrent imbalance.
484 J.L. Williams et al.genomic profiles emerge from the primary cohort: genomi-
cally unstable PTEN deleted tumors and simpler PTEN intact
tumors.
CNAs and candidate genes associated with PTEN
deletions or fusion gene positivity
A statistical comparison of the regions of CNAs associated with
either thepresenceof the fusiongeneor the presenceof aPTEN
deletion was made using circos plots (Figure 4xie4xii). In these
analyses, the candidate driver genes (see Figure 2) were
assigned to regions of recurrent imbalance. The fusion-positive
samples were associated with deletions at 3p13 (FOXP1,
EIF4E3, RYBP, and SHQ1, P Z 5.95  105), 8p (NKX3-1,
P Z 0.003), 10q23.31 (PTEN, P Z 7.7  105), 16q
(PZ 2.4 104), and 17p (TP53,PZ 4.8 105) (Figure 4xi).
PTENdeletedsamples (Figure4xii) hadahighconcordancewith
deletions at 3p13 (FOXP1, EIF4E3, RYBP, and SHQ1,
PZ 1.95  106), 8p (NKX3-1, PZ 2.3  1012), 10q regions
adjacent toPTEN (PZ1.11011), 13q (RB1,PZ3.4106),
16q (P Z 5.4  105), 17p (TP53, P Z 5.9  1019), and
21q22.2eq22.3 (gene fusion,PZ 1.95 106), as well as gain
of 8q (MYC, PZ 6.8  107). Based on the magnitude of the
P-values, the likelihood of association between PTEN and its
recurrent CNA regionswasmore significant than the association
levels found for the fusion gene. Taken together, these findings
continue to support the notion thatPTEN deletions are sufficient
to impose higher levels of CNA and overall genetic diversity.
Genomic instability metric
To compare overall levels of genomic instability in those tu-
mors with a PTEN genomic deletion to those without an
apparent deletion, the percentage of base pairs lost orgained relative to the entire genome was used to calculate
the PGA. A significant difference (P < 0.001) in PGA was
observed when segregating the primary cohort based on
deletion of the PTEN genomic region (Table S5, PTEN intact,
PGA Z 5.4%; and PTEN loss, PGA Z 13.3%). There was
also a significantly greater frequency and number of CNAs
as well as a larger PGA in samples with deletion of the PTEN
locus (Figure 5A and 5B). Conversely, division of the cohort
based on fusion status did not yield a significant difference
(P Z 0.25) in terms of CNA frequency or PGA (Table S5,
fusion-negative, PGA Z 6.9%; and fusion-positive,
PGA Z 7.9%). The frequency of deletions was higher in
the fusion-positive samples only for 8p and 16q. Similarly, no
difference was observed with respect to the frequency of
gains across the genome (Figure 5C and 5D).Pathways implicated by the influence of CNAs on
gene expression in genomic subgroups
Ingenuity Pathway Analysis “Core Analysis” determined
significant networks, biological functions, and canonical
pathways associated with each genomic subgroup: B, C1,
C2, C3; PTEN intact, PTEN loss; fusion-positive, and fusion-
negative (Figure 6, Figure S12).
Cancer was the most significant biological function across
all eight subgroups; however, the PTEN loss group had the
most significant number (1,461) of input genes overlapping
with the “Cancer” function. “DNA Replication, Recombina-
tion, and Repair” and “Cell Cycle” were found in the top five
“Molecular and Cellular Functions” and were significantly
altered in the unsupervised genomic subgroups containing
PTEN genomic deletions (B (33 genes), C2 (46 genes), and
C3 (44 genes)) but not in the C1 group, which lacked
PTEN deletions. The “Telomere Extension by Telomerase”
Figure 5 Genomic instability with respect to PTEN and fusion genomic subdivisions. A significant difference (P < 0.001) was
observed when segregating the primary cohort based on deletion of the PTEN genomic region. (A) The line graph demonstrates the
percentage of primary prostate cancer samples (nZ 546) that contained deletions (right) or gains (left) across the genome (Table S3
for region limitations). At every point, PTEN deleted samples have a greater frequency of aberration when compared with PTEN intact
samples. (B) Furthermore, an increased proportion of the genome is deleted and gained in samples that have a deletion of PTEN. (C)
Segregation of the cohort based on fusion status alone does not yield a significant difference (PZ 0.25). The 8p and 16q deletions are
slightly elevated, and 2q deletions are fewer in the fusion-positive samples; otherwise, no difference exists based on fusion status. (D)
Similarly, the proportion of the genome altered is comparable between fusion-positive and fusion-negative samples.
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with the C genomic subgroups, which suggested a connec-
tion with the 8p deletion, the common factor between these
samples. Differences between the supervised classification
subgroups based on the fusion gene were almost completely
lacking; 3, 2, and 2 of the top “Diseases and Disorders”,
“Molecular & Cellular Functions”, and “Physiological System
Development and Function”, respectively, were the same
between both fusion-negative and fusion-positive samples.The PTEN deletion that was used to supervise classification
of the primary cohort successfully established that the ma-
jority of PTEN deleted genomes were associated with cancer
progression and metastasis. The top five PTEN deleted
“Molecular & Cellular Functions”, which comprised 1,029
genes, were: Cellular Movement; Cell Death and Survival;
Cellular Growth and Proliferation; Cellular Development; and
Drug Metabolism. The top five PTEN intact “Molecular &
Cellular Functions”, which comprised only 163 genes, were:
Canonical pathways Biological funcƟons
Subgroup B
Subgroup C1
Subgroup C2
Subgroup C3
Fusion-negaƟve
Fusion-posiƟve
Figure 6 The number of significantly perturbed canonical
pathways and biological processes for each primary prostate
cancer genomic subgroup are identified in this figure.
486 J.L. Williams et al.Cell Cycle; DNA Replication, Recombination, and Repair;
Cell Death and Survival; Gene Expression; and RNA Post-
transcriptional Modification. “DNA Replication, Recombina-
tion, and Repair” was not found in the top five in the PTEN
deleted group. Nevertheless, it was still altered significantly,
with 111 genes contributing to this biological function,
whereas only 36 genes were included in the PTEN intact
group, despite the fact that it was found in the top five. Both
unsupervised genomic subgroups and supervised classifi-
cation using the gene fusion provided limited differences;
however, supervised classification using PTEN deletions led
to numerous significant differences in canonical signaling
pathways as well as biological functions. These observations
further support the significance of stratifying primary prostate
cancer based on PTEN deletion status.Discussion
Prostate cancer has a variable clinical course, and recent
characterizations of CNAs have revealed marked genomic
heterogeneity that may help explain the differences in prog-
nosis (35). One of the historical limitations of attempting
genomic subgroup analysis has been the small cohort size
of individual studies. This is the first meta-analysis to
address this problem and to systematically examine publicly
accessible prostate cancer genomic datasets to derive a
consensus map of the most frequent CNAs in 662 prostate
cancers comprising 546 primary tumors and 116 from
advanced disease. This large cohort size allowed us to
stratify the CNAs into distinct genomic subgroups, and to
demonstrate that there were potential pathways that might
be deregulated by changes in gene expression arising from
the recurrent genomic imbalance that characterized the in-
dividual subgroups.
At present, less evidence exists regarding molecular
subtypes based on somatic mutations in prostate cancer
according to next generation sequencing approaches
(36e39). The recurrent mutation frequency at the sequence
level remains relatively low, with changes in copy number or
physical position (rearrangements) being more common than
somatic mutations (37,40,41). Although localized sequence
mutations do occasionally target important cancer genes,
albeit at a low frequency, CNAs seem to be much more
prevalent. Since recurrent CNAs can significantly reduce theexpression levels of tumor suppressors (PTEN, TP53, RB1)
by deletion, as well as increase the expression of oncogenes
(MYC, ERG) by gains, amplifications, or rearrangements,
there remains considerable interest in classifying prostate
cancer based on the patterns of recurrent CNAs.
In keeping with the published literature, deletions at 8p
(NKX3-1), 13q (RB1), 16q, and 6q were the most frequent
overall CNA losses observed in the cohort. Consistent inter-
stitial focal deletions included the tumor suppressor genes
PTEN at 10q23.31 and TP53 at 17p13.1. Other frequent focal
deletions involved 3p13 (FOXP1, RYBP, and SHQ1 gene
losses) and the 2.9 Mb deletion at 21q22.2eq22.3, which is
required to generate the common TMPRSS2-ERG genomic
fusion. The most frequent CNA gains affected the majority of
the 8q arm (MYC ) and all of chromosome 7.
PTEN deletions were reported in 20e30% of primary
prostate cancers, and were recognized to have prognostic
significance with respect to earlier biochemical relapse (9,41)
and prostate cancerespecific death (33). Studies of
castration-resistant prostate cancer also showed that PTEN
deletions were present at a much higher frequency
(50e70%) (42,43). Although the prognostic significance of
ETS rearrangements remains unresolved (reviewed in (44)),
it is well-established that ERG fusion rearrangements are
more likely to occur when PTEN is deleted, and that the
presence of both alterations influences prostate cancer
prognosis (8,33,42). Consistent with these findings, both of
these genomic alterations were found to be significantly
associated in the overall cohort in this study. Moreover, there
was a significant marked increase in the proportion of cases
harboring both rearrangements in the 116 advanced disease
samples. Specific regions particularly associated with PTEN
deletions included deletions of 8p (NKX3-1, prostate-specific
tumor suppressor), 10q, 13q (RB1), 16q, 17p (TP53), and the
TMPRSS2-ERG gene fusion, as well as gain of 8q (MYC ).
Regions associated with the fusion rearrangement were
deletions at 3p13 (FOXP1), 8p (NKX3-1), PTEN deletions,
16q, and 17p (TP53), whereas fusion-negative samples had
a weak association with deletions of 2q (CXCR4).
Our analysis of the influence of PTEN deletion on the
overall pattern of CNAs in the primary meta-analysis cohort
demonstrated that more marked copy number differences
occurred, which affected wider regions of the genome, when
PTEN was lost. Thus, the overall pattern of CNA appeared to
be strongly influenced by the presence or absence of PTEN
genomic deletion. In contrast, the presence or absence of the
gene fusion did not seem to influence the overall trends of
CNAs in the entire dataset.
The PTEN protein is thought to maintain genomic stability
through pAKT-dependent mechanisms that inactivate
CHEK1 by pAKT, thus permitting cell cycle progression to
continue in the presence of DNA damage (45). If this model
is correct, then when genomic deletion of PTEN takes place,
the absence, or reduced levels, of PTEN protein will lead to
pAKT activation and the accumulation of CNAs as a result of
unresolved DNA damage. However, there have been con-
flicting results with respect to non-canonical mechanisms of
PTEN’s function in maintaining genomic integrity. Several
groups have shown that lack of PTEN protein correlates with
a reduction in RAD51 foci (46,47) and an increase in gH2AX
foci (48,49), whereas other groups have demonstrated no
association of PTEN with RAD51 expression or foci (50,51).
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multiple cell cycle progression checkpoints, some of which
have downstream effects leading to defective DNA double-
strand break repair.
In addition to genomic deletion, the PTEN protein can be
lost as a result of indels, small DNA point mutations, or
promoter methylation of the PTEN gene (30,42). Thus, the
possibility exists that our supervised analyses of PTEN
genomic losses based on CNA detection may not have
detected all tumors with a PTEN protein loss, and may have
introduced bias into our analysis of the influences of PTEN
deletion on overall levels of CNAs. However, since it is
estimated that only 11% of prostate cancers have intragenic
somatic mutations of PTEN (3) and aberrant promoter
methylation of the PTEN gene appears to be rare (42), our
supervised classification of PTEN deletions is unlikely to
have been significantly affected.
Collectively, this in silico meta-analysis has demonstrated
that deletion of PTEN is associated with genomic instability
and other oncogenic changes, such as formation of the
TMPRSS2 gene fusion and loss of tumor suppressor
genomic regions containing RB1 and TP53. Moreover, the
overall pattern of genomic change found in PTEN deleted
primary tumors most closely resembles the CNA distribution
present in metastatic disease (Figure 2). These findings are
in agreement with a crucial oncogenic role for PTEN as a
primary driver gene in prostate cancer (10,52,53). Interest-
ingly, a recent in silico study of expression datasets, based
on integrative network analysis, showed that the PTEN pro-
tein was an independent prognostic biomarker of biochem-
ical recurrence-free survival in prostate cancer (54). This
finding is in keeping with our pathway analysis, which also
indicated that PTEN deleted tumors had the most signifi-
cantly distorted biological functions, highlighting cancer, cell
death/survival, and cellular movement in keeping with the
PTEN protein’s pivotal prognostic role.
The costs and feasibility of sequencing andCNAanalysis are
continually decreasing. Thus, using publicly available genomic
data to provide novel genomic subclassifications in tumors will
become increasingly important. Such approaches provide
combined evidence from multiple studies to indicate which bio-
logically relevant pathways should be pursued for clinical utility,
prognostic significance, and stratification of patients.Acknowledgments
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